February 5, 2013

ZALTRAP® (aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer

First and only agent to statistically significantly improve survival in combination with FOLFIRI chemotherapy after an oxaliplatin regimen

 

ZALTRAP® (aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer
First and only agent to statistically significantly improve survival in combination with FOLFIRI chemotherapy after an oxaliplatin regimen

Paris, France and Tarrytown, NY – February 5, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) granted marketing authorization in the European Union for ZALTRAP® (aflibercept) 25mg/ml concentrate for solution for infusion in combination with irinotecan/5- fluorouracil/folinic acid (FOLFIRI) chemotherapy in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen. This decision was based on the efficacy and safety results of the VELOUR Phase III trial.